Heart Test Laboratories Inc (HSCS)

[Deeznuts]

Massive dilution by company

[TimeFades]

Looks like she’s about ready

[TimeFades]

Yawn , do or die by weeks end here imho

[1hot toddy]

they have a year. y would they even bring it up to vote. it will get voted down now. where do u see that they are thinking about it? i will vote noooooo

[1hot toddy]

i see it. im voting nooooooooooo now

[1hot toddy]

they have a year. y would they even bring it up to vote. it will get voted down now. where do u see that they are thinking about it? i will vote noooooo

[Sunset Kid]

News out... the anticipated r/s vote is on Jan 4th, unless we can get close to $1 by then, no record date set. They actually have until 11-22-24 to comply with min. share price I believe according to latest sec filing (8k filed yesterday, the Company remains subject to a Nasdaq Panel Monitor through November 22, 2024).

[TimeFades]

After hours loading opps took her down and rinsing . Wouldn’t be suprised to see new highs tmrw

[Whalatane]

This Co ( Mayo Clinic spin off ? ) appears to have first mover advantage .
https://anumana.ai
Kiwi

[Whalatane]

In late September 2023, the FDA cleared an algorithm for low ejection fraction (less than 40%) under the 510(k)-pathway using the new product code. Accordingly, we now believe it is probable that we could submit the MyoVista algorithm for clearance under the 510(k) pathway. The 510(k) pathway is more common than De Novo and, on average, has a much quicker decision process than De Novo by the FDA.
We have formally filed the request with the FDA and expect a response in late Q4 2023.

Likely to be make or break for this Co
JMO
Kiwi

[Whalatane]

Heart Test Laboratories 13G Filing Shows ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ("ISMMS") EIN 13-6171197 Reported 9.9% Stake In Co As Of November 16, 2023

Kiwi

[TimeFades]

Heading to 30s soon whales soaking

[1hot toddy]

WOOOOOOOOOOOOW 109000 SHARE BUY $$$$$$$$$

[TimeFades]

Nice set up for tmrw

[1hot toddy]

big buys after market 25000 and 20000 shares. bunch of huge buys lately

[TimeFades]

Squeezy wonder

[TimeFades]

Icahn Money, could start a rally

[trendzone]

As usual the low life low level criminally run small hedge funds, that only have the ability to short small stocks,are at work since Wednesday shorting this one, these criminals that target these kind of stocks probably had a short position dating back before this week's little run up, being the low life criminals that they are, probably started shorting more on the run up to knock it back,so they didn't get squeezed out, these dirt bags could use a good old fashioned squeezing.

[Whalatane]

https://www.jacc.org/doi/10.1016/j.jacc.2020.07.001
https://www.jacc.org/doi/10.1016/j.jacc.2020.06.061

Kiwi

[Whalatane]

Form 8-K filed with the SEC on November 17, 2023: (i) the sale of shares of the Company’s common stock for approximately $6.2 million in gross proceeds;
---------------
So the Co lives to fight another day ......in this case for a lot longer .
Very speculative and a lot riding on FDA guidance re pathway for approval , patent protection etc
Small long position
Kiwi

[diskman]

That's the way I like it $$$$$$

[1hot toddy]

big buys 127000 shares and 89000 shares. $$$$$$$$$$$$$$ up up and away

[Golden Cross]

Nice news

[subslover]

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), in New York, NY, to develop and commercialize electrocardiographic AI algorithms and assets. The licenses result in Icahn Mount Sinai becoming a shareholder in the Company.

Andrew Simpson, Chief Executive Officer of HeartSciences, said, "We continue to advance initiatives that fundamentally transform and de-risk HeartSciences. The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs. Combined with the recent creation of a new FDA product classification for AI-ECG algorithms that we believe paves the way for a more structured and quicker 510(k) process of our technologies, we have clear focus on our target milestones," said Andrew Simpson, CEO of HeartSciences. “We believe AI-based ECG algorithms close the diagnostic gap to detect heart disease much earlier and at a lower cost and we look forward to accelerating commercialization and broadening the range of prospective solutions that we will provide.”

Erik Lium, PhD, the Chief Commercial Innovation Officer at the Mount Sinai Health System and President of Mount Sinai Innovation Partners, said, "We look forward to working with HeartSciences, a company that aims to bring new AI-powered ECG capabilities to market in an effort to enable the early detection of heart disease and, ultimately, improve the lives of patients."

The licenses from Icahn Mount Sinai grant rights to multiple patented and unpatented AI-based ECG/EKG algorithms and technologies for the screening and diagnosis of cardiovascular disease. The licenses provide HeartSciences with an industry leading library of AI-based ECG algorithms. HeartSciences intends to deliver these algorithms using a cloud-based, hardware agnostic platform, allowing HeartSciences to accept ECGs from millions of existing ECG devices around the world, including its MyoVista device. The algorithms were developed using a database of millions of ECG records, enabling researchers to develop a range of AI-based ECG algorithms using state-of-the art data science methods.

The AI cardiovascular algorithms are based on technology developed by Icahn Mount Sinai faculty and licensed by Mount Sinai to HeartSciences. Mount Sinai and Icahn Mount Sinai faculty, including Girish Nadkarni, MD, Irene and Dr. Arthur M. Fishberg Professor of Medicine at Icahn Mount Sinai, System Chief of the Division of Data-Driven and Digital Medicine (D3M), Co-Director of the Mount Sinai Clinical Intelligence Center (MSCIC), and Co-Director of The Charles Bronfman Institute for Personalized Medicine; Akhil Vaid, MD, Instructor in the Division of Data-Driven and Digital Medicine (D3M) at Icahn Mount Sinai; Joshua Lampert, MD, Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital; Vivek Reddy, MD, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn Mount Sinai; and Son Duong, MD, Assistant Professor of Pediatrics (Pediatric Cardiology) at Icahn Mount Sinai, have a financial interest in this technology and in HeartSciences. The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® Device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For Investor and Media Inquiries, please contact:

HeartSciences
Gene Gephart
[phone] (US)
[e-mail]

[GolfnutBoston]

When reverse split ?

[DERBYBLOOD]

HSCS - 7.6 mill float... she's going to take off very soon. Recent news just too good baby

[subslover]

Nothing. Better luck tomorrow with something else imho

[abazaba375]

Technically it’s worth a watch

[abazaba375]

What’s up here

[abazaba375]

Sublama

[TheFinalCD]

thats utterly shamtastic


LL

[subslover]

It's a travesty of a mockery of a sham of a mockery of two mockeries of a sham.

[TheFinalCD]

turd just went red

practically all buyers are down on this dog crap

[TheFinalCD]

42 pm to .18 what a poc

[TheFinalCD]

GAP & TRAPPER


on the verge of going red
#disgusting

[subslover]

Its a dog with fleas

[alchemytrader]

1.95k in revenue...lol

[subslover]

HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd (“Cardiact”) to be used in its heart screening program of members of the Association of Garda Sergeants and Inspectors (“AGSI”). In addition to the purchase of a MyoVista® device, Cardiact has placed an initial supplies order covering 2,400 patient tests.

Cardiact is rolling out a newly established heart screening program for the AGSI, which represents sergeants and inspectors of the Garda Síochána national police service of Ireland (“Garda”), to be conducted across Ireland and is due to commence on November 27, 2023. Cardiact has also established a new referral pathway directly to cardiology as part of the program.

Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are delighted that the MyoVista® wavECG™ has been chosen for use in this heart screening program of Irish Garda officers. AI-ECG is beginning to see mainstream acceptance and we are excited to see this new screening program which further validates the enormous commercial opportunity for the MyoVista® and the role of AI-ECG in preventative testing.” Mr. Simpson added, “This latest announcement follows a number of recent positive developments which we believe fundamentally transform and de-risk HeartSciences. This includes our agreements with Icahn School of Medicine at Mount Sinai, which provides HeartSciences with what we believe is the largest AI-based ECG algorithm portfolio of any commercial organization. In addition, the AI-ECG industry continues to make exciting progress, with the recent creation of a new FDA product classification for AI-ECG algorithms which we expect to make clearance more structured and quicker under the 510(k) process. We believe AI-based ECG algorithms are the bridge that will finally allow front-line healthcare professionals to close the diagnostic gap and detect heart disease much earlier and at a lower cost."

About HeartSciences

[OffTheGrid]

Adding .15

[abazaba375]

Yeah I actually sold way to soon but made a bit

[BIOCHEMUP]

You out completely from YCRM? What a shit show it has become, agreement terminated.

[abazaba375]

Dubs coming bud

[harry crumb]

No, after another 6 months trading this maybe, another 2.5m will be nice$$$$$$

[Invest-in-America]

HSCS:

[kbaz]

Take some Bounce and watch for a possible follow through leg up. Gotta act Fast!!!!

[SavageSoutherner]

Entire market is down but my stocklist is exploding .....fkn corruption at its finest. Our Gov't is trash af.

[TheFinalCD]

nice job cutting out before the extra pain

[kbaz]

May not be done just yet!!!!!

[TheFinalCD]

.222 WHAT A BS GAP & TRAP

[SavageSoutherner]

Ya'll realize it went to .80 last nite